Dermata Therapeutics (DRMA) just unveiled an announcement.
Dermata Therapeutics, Inc. stockholders, in their 2024 Annual Meeting, have greenlit a significant amendment to their equity incentive plan which will increase the number of shares reserved for issuance and the annual addition of shares. Additionally, they approved a reverse stock split, appointed Moss Adams LLP as their independent accounting firm for the year, and passed a measure to adjourn the meeting if there weren’t enough votes for key proposals. The election of three directors to the board was confirmed with a majority vote.
For an in-depth examination of DRMA stock, go to TipRanks’ Stock Analysis page.
